Literature DB >> 15988140

Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin.

Yoshitaka Matsumoto1, Hikaru Machida, Nobuo Kubota.   

Abstract

The purpose of this study was to investigate the radiosensitizing effect of geldanamycin (GA), an inhibitor of heat shock protein 90, on tumour cells and normal cells. We tested the effect of a combination of GA and radiation on cell survival, PI3K/Akt-related proteins and apoptosis induction. GA sensitized tumour cells to radiation in preference to normal cells. In addition, a combination of radiation and GA abolished Akt activities and strongly enhanced the induction of apoptosis in tumour cells which depend on Akt protein activities for cell survival. The present data support the hypothesis that GA sensitizes tumour cells by modulating the balance among mitogenic, antiproliferative and apoptotic pathways. Targeting Hsp90 in tumour cells may lead to the development of new radiosensitizing strategies in radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15988140     DOI: 10.1269/jrr.46.215

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  14 in total

1.  Heat shock protein 90α (Hsp90α) is phosphorylated in response to DNA damage and accumulates in repair foci.

Authors:  Maria Quanz; Aurélie Herbette; Mano Sayarath; Leanne de Koning; Thierry Dubois; Jian-Sheng Sun; Marie Dutreix
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

2.  A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.

Authors:  Steven H Lin; Jing Zhang; Uma Giri; Clifford Stephan; Mary Sobieski; Ling Zhong; Kathy A Mason; Jessica Molkentine; Howard D Thames; Stephen S Yoo; John V Heymach
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

3.  Down-regulation of heat shock protein HSP90ab1 in radiation-damaged lung cells other than mast cells.

Authors:  Michael G Haase; Peter Geyer; Guido Fitze; Gustavo B Baretton
Journal:  J Histochem Cytochem       Date:  2014-03-26       Impact factor: 2.479

Review 4.  Hsp90 inhibitors as promising agents for radiotherapy.

Authors:  Alexander E Kabakov; Vladimir A Kudryavtsev; Vladimir L Gabai
Journal:  J Mol Med (Berl)       Date:  2009-11-28       Impact factor: 4.599

5.  Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Authors:  Nishant Gandhi; Aaron T Wild; Sivarajan T Chettiar; Khaled Aziz; Yoshinori Kato; Rajendra P Gajula; Russell D Williams; Jessica A Cades; Anvesh Annadanam; Danny Song; Yonggang Zhang; Russell K Hales; Joseph M Herman; Elwood Armour; Theodore L DeWeese; Edward M Schaeffer; Phuoc T Tran
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

6.  Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.

Authors:  Robert M Immormino; Louis E Metzger; Patrick N Reardon; D Eric Dollins; Brian S J Blagg; Daniel T Gewirth
Journal:  J Mol Biol       Date:  2009-04-08       Impact factor: 5.469

7.  HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.

Authors:  Thuy T Koll; Steven S Feis; Mollie H Wright; Modupe M Teniola; Mekel M Richardson; Ana I Robles; John Bradsher; Jacek Capala; Lyuba Varticovski
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

8.  Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature.

Authors:  Tomoyuki Miyagawa; Hajime Saito; Yoshihiro Minamiya; Kazutaka Mitobe; Shinogu Takashima; Naoko Takahashi; Aki Ito; Kazuhiro Imai; Satoru Motoyama; Junichi Ogawa
Journal:  Int J Clin Oncol       Date:  2013-08-15       Impact factor: 3.402

9.  The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.

Authors:  Shane Zaidi; Martin McLaughlin; Shreerang A Bhide; Suzanne A Eccles; Paul Workman; Christopher M Nutting; Robert A Huddart; Kevin J Harrington
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

Review 10.  Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.

Authors:  Sara Alcorn; Amanda J Walker; Nishant Gandhi; Amol Narang; Aaron T Wild; Russell K Hales; Joseph M Herman; Danny Y Song; Theodore L Deweese; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.